SABCS 2020 | ASCENT: sacituzumab govitecan biomarker analysis
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, outlines the updated biomarker analysis results of the ASCENT trial (NCT02574455), a Phase III study evaluating the efficacy of sacituzumab govitecan, a novel antibody-drug conjugate against physicians choice chemotherapy in patients with metastatic, triple-negative breast cancer. Trop-2 and BRCA expression was evaluated in these patients to determine whether these markers correlated with the efficacy of the antibody-drug conjugate. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.
